Alzheimer's disease occurs in middle and late life and is defined clinically by a dementia syndrome. The natural history and risks/prognostic factors are not clear, and the causes remain unknown. No effective therapy is yet available. Analyses of brain tissue reveal degeneration of specific neuronal populations and the presence of senile plaques and neurofibrillary tangles. Alterations in transmitter-specific markers including those of the basal forebrain cholinergic systems and, in some cases, of the noradrenergic, somatostatingeric, and other system have also been reported. At present, the relationships between clinical abnormalities and the chemical and structural pathology of the brain are not clear. The principal goals of the Alzheimer's Disease Research Center (ADRC) are to provide the staff, environment, shared resources, and ideas for clinical neuropathological and neurochemical investigations of these problems. The ADRC will provide: administrative staff (Core A); patient populations (Core B); biostatistical programs (Cores A, B, and C); neuropathological/neurochemical analyses (Core C); state-of-the-art computer-imaging technology for quantitating changes in numbers of nerve cells and in structural pathologies of specific neuronal components (Core C); and training/information transfer programs (Core D). In addition, the ADRC will support basic research on: the organization of the normal primate brain (Project A and Pilot C); changes in brain structure/function in aging (Project A); development and characterization of animal models resembling AD (Projects A and B and Pilot F); the issue of regeneration and repair processes in the central nervous system (Project B and Pilot A); and the development of new approaches to therapy of AD, including the use of trophic factors, such as nerve growth factor (Pilot D) and intracerebral grafts of neuronal cells (Pilots A and F). The long-term goal of the ADRC is to encourage new investigators and innovative research in this field so that we may eventually understand the abnormal biological processes occurring in Alzheimer-type dementia and, therefore, devise more rational treatments for these unfortunate individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-03
Application #
3104828
Study Section
Aging Review Committee (AGE)
Project Start
1984-09-28
Project End
1989-08-31
Budget Start
1986-09-01
Budget End
1987-06-30
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Seddighi, Sahba; Varma, Vijay R; An, Yang et al. (2018) SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. J Alzheimers Dis 61:401-414
Fredericks, Carolyn A; Sturm, Virginia E; Brown, Jesse A et al. (2018) Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimers Dement (Amst) 10:471-479
Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
van Bergen, Jiri M G; Li, Xu; Quevenco, Frances C et al. (2018) Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiol Aging 64:68-75
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998

Showing the most recent 10 out of 830 publications